Marinus Pharmaceuticals Crecimiento futuro
Future controles de criterios 2/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Marinus Pharmaceuticals de 56.1% y 41.5% respectivamente, mientras que el BPA crecerá en un 59.1% al año.
Información clave
56.1%
Tasa de crecimiento de los beneficios
59.1%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Pharmaceuticals | 22.9% |
Tasa de crecimiento de los ingresos | 41.5% |
Rentabilidad financiera futura | n/a |
Cobertura de analistas | Good |
Última actualización | 17 Apr 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Might Not Be As Mispriced As It Looks After Plunging 86%
Apr 16Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 08Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?
Dec 22Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?
Sep 22Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S
Jun 12Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically
May 16Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts
Oct 26Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?
Oct 12Marinus Pharmaceuticals: Positive News Flow Of Note
Sep 22Marinus Pharma closes on sale of a U.S. FDA priority review voucher for $110M
Aug 29Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher
Aug 13Marinus Pharmaceuticals Q2 2022 Earnings Preview
Aug 10Marinus Pharma announces U.S. commercial launch of seizure therapy Ztalmy
Jul 28Revisiting Marinus Pharmaceuticals
May 05Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenues
Mar 27Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?
Mar 03Marinus Stock Slides To 18-Month Low, Upcoming PDUFA May Offer Redemption
Feb 28Health Check: How Prudently Does Marinus Pharmaceuticals (NASDAQ:MRNS) Use Debt?
Nov 04Marinus Pharmaceuticals (MRNS) Investor Presentation - Slideshow
May 26We're Hopeful That Marinus Pharmaceuticals (NASDAQ:MRNS) Will Use Its Cash Wisely
Apr 14Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2026 | 133 | -30 | 36 | N/A | 6 |
12/31/2025 | 62 | -94 | -46 | N/A | 11 |
12/31/2024 | 41 | -133 | -58 | N/A | 11 |
12/31/2023 | 31 | -141 | -118 | -118 | N/A |
9/30/2023 | 31 | -134 | -113 | -113 | N/A |
6/30/2023 | 26 | -28 | -119 | -117 | N/A |
3/31/2023 | 22 | -35 | -128 | -127 | N/A |
12/31/2022 | 25 | -20 | -115 | -113 | N/A |
9/30/2022 | 20 | -14 | -115 | -113 | N/A |
6/30/2022 | 28 | -105 | -80 | -78 | N/A |
3/31/2022 | 28 | -91 | -69 | -67 | N/A |
12/31/2021 | 15 | -99 | -58 | -55 | N/A |
9/30/2021 | 15 | -88 | -52 | -50 | N/A |
6/30/2021 | 5 | -84 | -71 | -70 | N/A |
3/31/2021 | 4 | -76 | -63 | -63 | N/A |
12/31/2020 | 2 | -76 | -61 | -61 | N/A |
9/30/2020 | 0 | -74 | -61 | -61 | N/A |
6/30/2020 | N/A | -72 | -58 | -58 | N/A |
3/31/2020 | N/A | -69 | -51 | -51 | N/A |
12/31/2019 | N/A | -54 | -49 | -49 | N/A |
9/30/2019 | N/A | -49 | -42 | -42 | N/A |
6/30/2019 | N/A | -46 | -37 | -36 | N/A |
3/31/2019 | N/A | -43 | -34 | -33 | N/A |
12/31/2018 | N/A | -37 | -28 | -28 | N/A |
9/30/2018 | N/A | -31 | -23 | -23 | N/A |
6/30/2018 | N/A | -24 | -20 | -19 | N/A |
3/31/2018 | N/A | -19 | -18 | -18 | N/A |
12/31/2017 | N/A | -19 | -19 | -19 | N/A |
9/30/2017 | N/A | -20 | N/A | -20 | N/A |
6/30/2017 | N/A | -22 | N/A | -24 | N/A |
3/31/2017 | N/A | -27 | N/A | -26 | N/A |
12/31/2016 | N/A | -29 | N/A | -25 | N/A |
9/30/2016 | N/A | -30 | N/A | -24 | N/A |
6/30/2016 | N/A | -29 | N/A | -23 | N/A |
3/31/2016 | N/A | -25 | N/A | -22 | N/A |
12/31/2015 | N/A | -25 | N/A | -20 | N/A |
9/30/2015 | N/A | -21 | N/A | -17 | N/A |
6/30/2015 | N/A | -18 | N/A | -14 | N/A |
3/31/2015 | N/A | -17 | N/A | -11 | N/A |
12/31/2014 | N/A | -13 | N/A | -9 | N/A |
9/30/2014 | N/A | -12 | N/A | -10 | N/A |
6/30/2014 | N/A | -12 | N/A | -8 | N/A |
3/31/2014 | N/A | -11 | N/A | -7 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que MRNS siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que MRNS siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que MRNS siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (41.5% al año) de MRNS crezcan más rápidamente que los del mercado US (8.1% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (41.5% al año) de MRNS crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de MRNS se prevé que sea elevada dentro de 3 años.